Hospital Universitari de Girona Dr. Josep Trueta -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

    Biomedicine and Pharmacotherapy, Vol. 176

2023

  1. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

    Cells, Vol. 12, Núm. 6

2022

  1. Endocannabinoid signaling of homeostatic status modulates functional connectivity in reward and salience networks

    Psychopharmacology, Vol. 239, Núm. 5, pp. 1311-1319

  2. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

    Multiple Sclerosis and Related Disorders

  3. Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice

    Cancers, Vol. 14, Núm. 24

2016

  1. A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women

    PLoS ONE, Vol. 11, Núm. 2

  2. Modulation of irisin and physical activity on executive functions in obesity and morbid obesity

    Scientific Reports, Vol. 6

2013

  1. Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans

    PLoS ONE, Vol. 8, Núm. 6

2012

  1. Executive functions profile in extreme eating/weight conditions: From Anorexia Nervosa to Obesity

    PLoS ONE, Vol. 7, Núm. 8